Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians.
Activities of Daily Living
Adaptation, Psychological
Adult
Aged
Caregivers
Disease Susceptibility
Family
Female
Focus Groups
Health Personnel
Humans
Huntington Disease
/ physiopathology
Male
Middle Aged
Patient Safety
Prodromal Symptoms
Qualitative Research
Quality of Life
Social Interaction
Social Stigma
Chorea
Huntington’s disease
focus groups
qualitative
quality of life
Journal
Neuropsychological rehabilitation
ISSN: 1464-0694
Titre abrégé: Neuropsychol Rehabil
Pays: England
ID NLM: 9112672
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
pubmed:
9
3
2019
medline:
26
2
2021
entrez:
9
3
2019
Statut:
ppublish
Résumé
Chorea, a hallmark symptom of Huntington's disease (HD), is characterized by jerky involuntary movements affecting the whole body that can interfere with daily functioning and impact health-related quality of life (HRQOL). To characterize chorea's impact on everyday functioning and HRQOL and identify patterns of perception and experiences of chorea among patients, caregivers, and providers. Data from focus groups of individuals with manifest HD (
Identifiants
pubmed: 30849283
doi: 10.1080/09602011.2018.1564675
pmc: PMC7685000
mid: NIHMS1534518
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1150-1168Subventions
Organisme : NINDS NIH HHS
ID : R03 NS065194
Pays : United States
Références
J Mark Access Health Policy. 2016 Oct 13;4:
pubmed: 27826381
Drugs. 2010 Mar 26;70(5):561-71
pubmed: 20329804
P T. 2008 Dec;33(12):690-4
pubmed: 19750050
Health Qual Life Outcomes. 2017 Jan 7;15(1):6
pubmed: 28069034
JAMA. 2016 Jul 5;316(1):33-5
pubmed: 27380339
Mov Disord. 2017 Jul;32(7):1096-1102
pubmed: 28556412
Mov Disord. 2010 Dec 15;25(16):2838-44
pubmed: 20960478
Tremor Other Hyperkinet Mov (N Y). 2014 Apr 14;4:224
pubmed: 24757585
Parkinsonism Relat Disord. 2018 Apr;49:42-47
pubmed: 29326033
J Spinal Cord Med. 2015 May;38(3):335-46
pubmed: 26010968
Consult Pharm. 2009 Jul;24(7):524-37
pubmed: 19689181
CNS Drugs. 2011 Dec 1;25(12):1073-85
pubmed: 22133328
Clin Neuropharmacol. 2008 May-Jun;31(3):127-33
pubmed: 18520979
Neurology. 2007 Mar 6;68(10):797; author reply 797
pubmed: 17339599
Qual Life Res. 2018 Mar;27(3):811-822
pubmed: 29222609
Clin Ther. 2012 Jul;34(7):1487-504
pubmed: 22749259
Mov Disord. 2009 Sep 15;24(12):1763-72
pubmed: 19562761
Mov Disord. 2014 Sep 15;29(11):1414-8
pubmed: 25156927
Int J Lang Commun Disord. 2010 May-Jun;45(3):381-93
pubmed: 20144006
Clin Rehabil. 2015 Feb;29(2):196-206
pubmed: 25142278
Behav Neurol. 2013;26(4):245-53
pubmed: 22713409
Psychol Assess. 2018 Apr;30(4):450-458
pubmed: 28557480
J Huntingtons Dis. 2013;2(2):159-75
pubmed: 25063513
Disabil Rehabil. 2010;32(11):917-28
pubmed: 19874213
J Neurol Phys Ther. 2013 Dec;37(4):149-58
pubmed: 24232362
J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):88-90
pubmed: 19091714
JAMA. 2016 Jul 5;316(1):40-50
pubmed: 27380342
Clin Rehabil. 2013 Jul;27(7):646-58
pubmed: 23426565
J Behav Health Serv Res. 2007 Oct;34(4):443-58
pubmed: 17351757
Qual Health Res. 2006 Apr;16(4):547-59
pubmed: 16513996
Clin Genet. 2011 Sep;80(3):235-9
pubmed: 21736564
Ann Pharmacother. 2010 Jun;44(6):1080-9
pubmed: 20442355
Mov Disord. 2009 Mar 15;24(4):574-8
pubmed: 19097181
Qual Life Res. 2016 Oct;25(10):2441-2455
pubmed: 27522213
JAMA Neurol. 2016 Dec 1;73(12):1404-1406
pubmed: 27749952
J Health Psychol. 2013 Feb;18(2):212-25
pubmed: 22427174
Mov Disord. 2008 Apr 15;23(5):721-6
pubmed: 18175350
J Neurol. 2016 Oct;263(10):2080-5
pubmed: 27435968
J Spinal Cord Med. 2015 May;38(3):326-34
pubmed: 26010967
Qual Life Res. 2016 Oct;25(10):2429-2439
pubmed: 27141833
Parkinsonism Relat Disord. 2016 Oct;31:46-52
pubmed: 27423921
Mov Disord. 2008 May 15;23(7):970-976
pubmed: 18381643
Mov Disord. 2012 Jan;27(1):31-41
pubmed: 21997232
J Health Psychol. 2005 Jul;10(4):597-612
pubmed: 16014395
J Neurol. 2018 Jan;265(1):98-107
pubmed: 29143208
J Appl Meas. 2010;11(3):315-30
pubmed: 20847478
Patient. 2018 Oct;11(5):547-559
pubmed: 29750428
J Huntingtons Dis. 2014;3(3):233-52
pubmed: 25300328
Qual Life Res. 2016 Oct;25(10):2403-2415
pubmed: 27393121
Prog Neurobiol. 2013 Nov;110:2-28
pubmed: 24036231
Soc Sci Med. 2004 Jan;58(1):137-49
pubmed: 14572927
Lancet. 2010 Jul 3;376(9734):18-9
pubmed: 20626094
Clin Neuropharmacol. 2002 Nov-Dec;25(6):300-2
pubmed: 12469001
BMC Fam Pract. 2005 Sep 14;6:38
pubmed: 16162290
Mov Disord. 2001 May;16(3):481-8
pubmed: 11391742
Neurology. 2003 Oct 28;61(8):1085-92
pubmed: 14581669
Am J Med Genet B Neuropsychiatr Genet. 2010 Jul;153B(5):1081-93
pubmed: 20468061
Neuropsychiatr Dis Treat. 2010 Oct 05;6:657-65
pubmed: 20957126
Neurosci Lett. 1995 May 26;191(3):141-4
pubmed: 7644133
Mov Disord. 2004 Mar;19(3):285-97
pubmed: 15022182
Arch Phys Med Rehabil. 2011 Oct;92(10 Suppl):S52-60
pubmed: 21958923
J Neuropsychiatry Clin Neurosci. 2018 Summer;30(3):194-201
pubmed: 29558861
Health Soc Care Community. 2015 Sep;23(5):569-76
pubmed: 25471490
Neurology. 1992 Jun;42(6):1232-8
pubmed: 1534875
Qual Life Res. 2016 Oct;25(10):2417-2427
pubmed: 27038054
Mov Disord. 2001 Mar;16(2):325-30
pubmed: 11295789
Am J Med Genet B Neuropsychiatr Genet. 2010 Sep;153B(6):1150-9
pubmed: 20468062
BMC Neurol. 2009 Dec 18;9:62
pubmed: 20021666
PLoS Curr. 2011 Nov 13;3:RRN1283
pubmed: 22139861
Mov Disord. 2012 Sep 15;27(11):1379-86
pubmed: 22975850
Trials. 2014 Dec 12;15:487
pubmed: 25494622
Semin Oncol. 1995 Apr;22(2 Suppl 3):73-81
pubmed: 7537908
Neurology. 2006 Feb 14;66(3):366-72
pubmed: 16476934
Med Lett Drugs Ther. 2009 Jan 26;51(1304):7-8
pubmed: 19172140
Mov Disord. 2004 Nov;19(11):1341-8
pubmed: 15389986
Qual Life Res. 2007 Jun;16(5):793-801
pubmed: 17375373
Exp Brain Res. 2012 May;218(4):639-54
pubmed: 22434341
Qual Health Res. 2002 Jul;12(6):855-66
pubmed: 12109729
Expert Opin Pharmacother. 2007 Feb;8(2):141-53
pubmed: 17257085